XUAN Zhe,XUE Xin-Dong,FU Jian-Hua. Research advance in prevention and treatment of bronchopulmonary dysplasia in premature infants[J]. 中国当代儿科杂志, 2010, 12(05): 412-416.
XUAN Zhe,XUE Xin-Dong,FU Jian-Hua. Research advance in prevention and treatment of bronchopulmonary dysplasia in premature infants[J]. CJCP, 2010, 12(05): 412-416.
[1]Fanaroff AA,Stoll BJ,Wright LL.Trends in neonatal morbidity and mortality for very low birthweight infants[J].Am J Obstet Gynecol, 2007, 196(2):147.e1-8.
[2]Jobe AH, Bancalari E. Bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2001, 163(7) :1723-1729.
[4]Collard KJ, Godeck S, Holley JE, Quinn MW. Pulmonary antioxidant concentrations and oxidatite damage in ventilated premature babies[J]. Arch Dis Child Fetal Neonatal Ed, 2004, 89(5):F412-F416.
[5]Bancalari E, Claure N, Sosenko IR.Bronchopulmonary dysplasia:changens in pathphogenesis, epidemiology and definition[J].Semin Neonatol, 2003, 8(1):63-71.
[11]Aukland SM, Halvorsen T, Fosse KR. High-resolution CT of the chest in children and young adults who were born prematurely: findings in a population-based study [J].AJR Am J Roentgenol, 2006, 187(4):1012-1018.
[12]Howling S, Northway W, Hansell DM.Pulmonary sequelae of bronchopulmonary dysplasia survivors: highresolution CT findings[J].AJR Am J Roentgenol, 2000, 174(5):1323-1326.
[13]Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers[J]. Pediatrics,1987, 79(1):26-30.
[14]Davis PG, Henderson-Smart DJ.Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants[J]. Cochrane Database Syst Rev, 2003(2):CD000143.
[15]De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates[J].Cochrane Database Syst Rev, 2008, 23(1):CD002977.
[16]Mariani G, Cifuentes J, Carlo WA.Randomized trial of permissive hypercapnia in preterm infants[J]. Pediatrics, 1999, 104(5):1082-1088.
[17]Carlo WA, Stark AR, Wright LL.Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants[J].J Pediatr, 2002, 141(3):370-374.
[18]Miller JD, Carlo WA .Safety and effectiveness of permissive hypercapnia in the preterm infant[J].Curr Opin Pediatr, 2007, 19(2):142-144.
[19]Thome UH, Carroll W, Wu TJ, Johnson RB, Roane C, Young D, et al .Outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life[J]. Biol Neonate, 2006, 90(4):218-225.
[20]Ambalavanan N, Carlo WA.Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia[J].Semin Perinatol, 2006, 30(4):192-199.
[21]Deulofeut R, Critz A, Adams-Chapman I, Sola A.Avoiding hyperoxia in infants or=1250g is associated with improved short-and long-term outcomes[J]. J Perinatol, 2006, 26(11):700-705.
[22]Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM .Oxygen-saturation targets and outcomes in extremely preterm infants [J]. N Engl J Med, 2003, 349(10):959-967.
[24]Halliday HL, Ehrenkranz RA, Doyle LW.Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2003, (1):CD001144.
[25]Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH,Mammel MC,et al.Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial[J].Pediatrics, 2004, 114(6):1649-1657.
[26]Shah V, Ohlsson A, Halliday HL, Dunn MS .Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates[J].Cochrane Database Syst Rev, 2007, 17(4):CD001969.
[27]Soll RF, Blanco F.Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome[J].Cochrane Database Syst Rev, 2001(2): CD000144.
[28]Pfister RH, Soll RF, Wiswell T .Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome[J].Cochrane Database Syst Rev, 2007, 17(4):CD006069.
[29]Yost CC, Soll RF.Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome[J].Cochrane Database Syst Rev, 2000(2): CD001456.
[31]Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, et al.Inhaled nitric oxide in preterm infants undergoing mechanical ventilation[J]. N Engl J Med, 2006, 355(15):343-353.
[32]Viscardi R, Manimtim W, He JR, Hasday JD, Sun CC, Joyce B,et al .Disordered pulmonary myofibroblast distribution and elastin expression in preterm infants with Ureaplasma urealyticum pneumonitis[J].Pediatr Dev Patho, 2006, l9(2):143-151.
[33]Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL .Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum[J]. Cochrane Database Syst Rev, 2003(4):CD003744.
[34]Ballard HO, Anstead MI, Shook LA.Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study[J].Respir Res, 2007, 8:41.
[35]Lai NM, Rajadurai SV, Tan KH .Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/ chronic lung disease[J]. Cochrane Database Syst Rev, 2006(3):CD005093.
[36]Mataloun MM, Rebello CM, Mascaretti RS, Dohlnikoff M,Leone CR .Pulmonary responses to nutritional restriction and hyperoxia in premature rabbits[J].J Pediatr (Rio J) 2006, 82(3):179-185.
[37]Biniwale MA, Ehrenkranz RA.The role of nutrition in the prevention and management of bronchopulmonary dysplasia[J].Semin Perinatol, 2006, 30(4):200-208.
[38]Bhandari A, Bhandari V.Pitfalls, problems, and progress in bronchopulmonary dysplasia[J].Pediatrics, 2009, 123(6):1562-1573.